Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404014 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
A Phase 2 study, sponsored by Allon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT00404014 is a Phase 2 study that has completed, run by Allon Therapeutics. The registered enrollment target is 234 participants.
The verdict
NCT00404014, a Phase 2 study, has completed, sponsored by Allon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
Interventions
- DRUG Placebo
- DRUG AL-208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404014
The ClinicalTrials.gov registry entry for NCT00404014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allon Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00404014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404014 about?
NCT00404014 is a clinical study titled "Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery". The primary objective is to compare mild cognitive impairment in the AL-208 group with the placebo group at 14 + - 3 days after CABG surgery
What is the current status of trial NCT00404014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2006-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00404014?
The interventions under investigation include: Placebo (DRUG), AL-208 (DRUG).
Who is sponsoring clinical trial NCT00404014?
This trial is sponsored by Allon Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.